Exhibit 31Page 1

# CERTIFICATION PURSUANT
TO U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Milo R. Polovina, certify that:

1.    
I have reviewed this quarterly report on Form 10-QSB of Protide Pharmaceuticals,
Inc;

2.    
Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3.    
Based on my knowledge, the financial statement, and other financial information
included in this quarterly report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this quarterly report;

4.    
The registrants other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14and 15d-14) for the registrant and have:

a)    
designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

b)    
evaluated the effectiveness of the registrants disclosure controls and
procedures as of a date with 90 days prior to the filing date of this report (
the Evaluation Date), and

c)    
presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls based on our evaluation as of the Evaluation Date;

5.    
The registrants other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrants auditors and the audit
committee of the registrants board of directors (or persons performing the
equivalent functions):

a)    
all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrants ability to record, process,
summarize and report financial data and have identified for the
registrants auditor any material weaknesses in internal controls; and

b)    
any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrants internal controls; and

6.    
The registrants other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

|                           |                                                         |     |  |                        | 
|-------------------------- | ------------------------------------------------------- | --- |  | ---------------------- | 
|Dated:   January 13, 2004. |                                                         | By: |  | /s/   Milo R. Polovina | 
|                           |                                                        
|                           | Milo R. Polovina, Chairman of theBoard, President & CEO |    

15

---

Exhibit 31 Page 2

# CERTIFICATION PURSUANT
TO U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David E. Tess, certify that:

1.    
I have reviewed this quarterly report on Form 10-QSB of Protide Pharmaceuticals,
Inc;

2.    
Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3.    
Based on my knowledge, the financial statement, and other financial information
included in this quarterly report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this quarterly report;

4.    
The registrants other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14and 15d-14) for the registrant and have:

a)    
designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

b)    
evaluated the effectiveness of the registrants disclosure controls and
procedures as of a date with 90 days prior to the filing date of this report (
the Evaluation Date); and

c)    
presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls based on our evaluation as of the Evaluation Date;

5.    
The registrants other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrants auditors and the audit
committee of the registrants board of directors (or persons performing the
equivalent functions):

a)    
all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrants ability to record, process,
summarize and report financial data and have identified for the
registrants auditor any material weaknesses in internal controls; and

b)    
any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrants internal controls; and

6.    
The registrants other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

|                           |                                     |     |  |                     | 
|-------------------------- | ----------------------------------- | --- |  | ------------------- | 
|Dated:   January 13, 2004. |                                     | By: |  | /s/   David E. Tess | 
|                           |                                    
|                           | David E. TessVice President Finance |    

16

---